748,062 Shares in Xencor, Inc. $XNCR Purchased by Johnson & Johnson

Johnson & Johnson bought a new position in Xencor, Inc. (NASDAQ:XNCR) in the second quarter, HoldingsChannel reports. The fund bought 748,062 shares of the biopharmaceutical company’s stock, valued at approximately $12,043,798,000. Xencor makes up about 1.5% of Johnson & Johnson’s portfolio, making the stock its 8th largest position.

Several other hedge funds and other institutional investors have also bought and sold shares of XNCR. AQR Capital Management LLC bought a new stake in shares of Xencor in the first quarter worth approximately $438,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Xencor by 9.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,047 shares of the biopharmaceutical company’s stock valued at $471,000 after purchasing an additional 3,692 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Xencor by 89.9% during the first quarter. Goldman Sachs Group Inc. now owns 726,734 shares of the biopharmaceutical company’s stock valued at $7,732,000 after purchasing an additional 344,088 shares during the period. Creative Planning lifted its position in Xencor by 25.3% during the second quarter. Creative Planning now owns 18,130 shares of the biopharmaceutical company’s stock valued at $143,000 after purchasing an additional 3,661 shares during the period. Finally, JPMorgan Chase & Co. boosted its holdings in Xencor by 170.9% in the second quarter. JPMorgan Chase & Co. now owns 330,007 shares of the biopharmaceutical company’s stock worth $2,594,000 after purchasing an additional 208,182 shares during the last quarter.

Xencor Stock Up 1.5%

Shares of NASDAQ:XNCR opened at $23.34 on Friday. The stock has a market capitalization of $1.74 billion, a PE ratio of -10.76 and a beta of 0.85. The firm’s 50 day moving average price is $16.79 and its 200-day moving average price is $13.71. Xencor, Inc. has a twelve month low of $7.13 and a twelve month high of $23.45.

Xencor (NASDAQ:XNCR) last announced its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.51. The company had revenue of $51.22 million during the quarter, compared to analyst estimates of $18.89 million. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The firm’s quarterly revenue was up 17.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.41) earnings per share. Analysts expect that Xencor, Inc. will post -3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

XNCR has been the subject of a number of research analyst reports. JPMorgan Chase & Co. lifted their target price on shares of Xencor from $13.00 to $14.00 and gave the stock a “neutral” rating in a research report on Monday, May 11th. Wall Street Zen raised Xencor from a “strong sell” rating to a “hold” rating in a report on Saturday, August 8th. Zacks Research upgraded Xencor from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Truist Financial cut their price objective on Xencor from $29.00 to $27.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. Finally, Cantor Fitzgerald upped their price objective on Xencor from $43.00 to $44.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Five equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Xencor has an average rating of “Hold” and an average target price of $24.86.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.